Emerging Targeted Therapies for Castration-Resistant Prostate Cancer

Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamo, Vincenzo, Noto, Laura, Franchina, Tindara, Chiofalo, Giuseppe, Picciotto, Maria, Toscano, Giuseppe, Caristi, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364443/
https://www.ncbi.nlm.nih.gov/pubmed/22666217
http://dx.doi.org/10.3389/fendo.2012.00073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364443/
https://www.ncbi.nlm.nih.gov/pubmed/22666217
http://dx.doi.org/10.3389/fendo.2012.00073

Ejemplares similares